Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
| العنوان: | Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer |
|---|---|
| المؤلفون: | Wen-Ting Tang, Xin-Hua Yang, Fang Wang, Wen-Jian Cen, Ren-Jing Zhang, Jiao-Jiao Yang, Xiao-Meng Ji, Jian Yong Shao, Ya-Kang Long, Ziming Du, Li-Yue Sun |
| المصدر: | Cancer Medicine, Vol 10, Iss 19, Pp 6610-6617 (2021) Cancer Medicine |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, non‐small cell lung cancer, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, tumor mutational burden, Combination therapy, medicine.medical_treatment, immune checkpoint inhibitor, smoking, combination therapy, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Humans, Radiology, Nuclear Medicine and imaging, Lung cancer, Immune Checkpoint Inhibitors, Research Articles, RC254-282, Survival analysis, Retrospective Studies, Chemotherapy, Lung, business.industry, Clinical Cancer Research, High-Throughput Nucleotide Sequencing, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Prognosis, medicine.disease, Immune checkpoint, medicine.anatomical_structure, Cohort, Adenocarcinoma, Female, Immunotherapy, business, Research Article |
| الوصف: | Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy. Methods We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status. Results We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p The tumor mutational burden (TMB) value correlated with smoking status in lung adenocarcinoma patients, but not in lung squamous cell carcinoma patients in both NGS panels. The TMB value combined with smoking status might be used as a potential prognostic indicator for advanced non‐small cell lung cancer patients receiving immune checkpoint inhibitor combination therapy. |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30aa3c9328d2e1f703b5c82d1740ed60Test https://doi.org/10.1002/cam4.4197Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....30aa3c9328d2e1f703b5c82d1740ed60 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|